Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Macrophage Repolarization Using Cd44-Targeting Hyaluronic Acid–Polylactide Nanoparticles Containing Curcumin Publisher Pubmed



Farajzadeh R1, 2 ; Zarghami N1, 2 ; Seratinouri H2, 3 ; Momenijavid Z1, 2 ; Farajzadeh T4 ; Jalilzadehtabrizi S1, 2 ; Sadeghisoureh S1, 2 ; Naseri N5 ; Pilehvarsoltanahmadi Y1, 2, 3, 6
Authors

Source: Artificial Cells# Nanomedicine and Biotechnology Published:2018


Abstract

The aim of this study was to evaluate the efficiency of using a natural substance, curcumin, encapsulated in CD44-targeting hyaluronate–polylactide (HA-PLA) nanoparticles (NPs) for the modulation of macrophage polarity from the pro-inflammatory M1 to anti-inflammatory M2 phenotype. For this purpose, the characterization of the NPs was monitored using 1 HNMR, FTIR, DLS and FE-SEM. The effects of curcumin-encapsulated HA-PLA NPs on the viability of LPS/IFN-γ stimulated peritoneal macrophages were determined using MTT assay. The cellular uptake of free curcumin and nano-formulated curcumin was assessed using confocal microscopy. Also, the expression levels of iNOS-2 (M1 marker), Arg-1 (M2 marker) and also pro-inflammatory cytokines were measured by real-time PCR. Data showed that the nano-formulated curcumin with spherical shape, an average diameter of 102.5 nm and high cellular uptake was significantly less toxic to peritoneal macrophages. Furthermore, the nano-formulated curcumin effectively indicated a reduction in iNOS-2 and an increase in Arg-1 levels than free curcumin. The change in macrophage phenotype by curcumin-encapsulated HA-PLA NPs could suppress the inflammation in LPS/IFN-γ stimulated macrophages as evidenced by a major reduction in pro-inflammatory cytokines. Conclusively, the results suggested that the curcumin formulation with CD44-targeting HA-PLA NPs might be a promising platform for the treatment of inflammatory diseases. © 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Other Related Docs